Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rohit Goyal

Critical Care Medicine Fredericksburg, VA Medical Doctor

NPI 1881879724 CMS profile 267458

521 Park Hill Dr, Fredericksburg, VA 22401

Open in the dashboard

General payments

$95,201

694 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rohit Goyal of Fredericksburg, VA is reported in the CMS Open Payments database as having received $95,201 across 694 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,432 120
2024 General $17,612 142
2023 General $55,332 125
2022 General $5,747 103
2021 General $5,535 114
2020 General $689 40
2019 General $854 50

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rohit Goyal
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Rohit Goyal were reported at $9,432. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Rohit Goyal Critical Care Medicine median Middle half National median
2019 $854 $149 $51–$535 $163
2020 $689 $110 $30–$325 $114
2021 $5,535 $125 $34–$403 $132
2022 $5,747 $157 $49–$582 $149
2023 $55,332 $162 $56–$621 $160
2024 $17,612 $168 $53–$634 $164
2025 $9,432 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pulmonx Corporation $63,479 39 payments
  2. Intuitive Surgical, Inc. $8,345 21 payments
  3. United Therapeutics Corporation $6,790 27 payments
  4. AstraZeneca Pharmaceuticals LP $2,038 88 payments
  5. Ethicon Inc. $1,806 10 payments
  6. GlaxoSmithKline, LLC. $1,630 106 payments
  7. Noah Medical Corporation $1,073 2 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $1,053 56 payments
  9. Olympus Corporation of the Americas $1,039 8 payments
  10. ANI Pharmaceuticals, Inc. $810 31 payments
  11. Other $7,140 306 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $62,351 17 payments
  2. Food and Beverage $16,440 618 payments
  3. Travel and Lodging $11,314 36 payments
  4. Education $5,083 22 payments
  5. Gift $14 1 payment
Products named General payments · program years 2019–2025
  1. ZEPHYR ENDOBRONCHIAL VALVE $63,354 38 payments
  2. CHARTIS CATHETER $52,629 33 payments
  3. PULMONX CHARTIS TABLET CONSOLE $52,629 33 payments
  4. ZEPHYR DELIVERY CATHETER $52,629 33 payments
  5. Da Vinci Surgical System $8,345 21 payments
  6. Monarch Platform $1,806 10 payments
  7. SINGLE USE SUCTION VALVE (Sterile) $1,039 8 payments
  8. DUPIXENT $871 29 payments
  9. NUCALA $823 42 payments
  10. TEZSPIRE $814 18 payments
  11. Other $13,069 576 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,196

Median for Pulmonary Disease: 936

Drug cost

$896,884

Median for Pulmonary Disease: $487,987

Branded share of claims

68.2%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 17 $223,018
Prolastin C Alpha-1-Proteinase Inhibitor Brand 22 $178,588
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 177 $177,493
Glassia Alpha-1-Proteinase Inhibitor Brand 12 $104,008
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 66 $60,407
Breo Ellipta Fluticasone/Vilanterol Brand 68 $41,365
Spiriva Respimat Tiotropium Bromide Brand 27 $26,816
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 48 $25,130
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 24 $15,538
Symbicort Budesonide/Formoterol Fumarate Brand 27 $10,676

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$899,488

Of which drugs: $235,763

Medicare patients

1,733

Average age 75

Services billed

18,716

995 women, 738 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 57%
Arthritis 52%
Ischemic heart disease 51%
Diabetes 39%
Heart failure 36%
Atrial fibrillation 34%
Chronic kidney disease 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, benralizumab, 1 mg J0517 Office 14 600 $78,849
Injection, mepolizumab, 1 mg J2182 Office 12 3,000 $71,621
Pcv20 vaccine im 90677 Office 59 59 $17,122
Vaccine for influenza for injection into muscle 90662 Office 48 48 $3,908

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$466 — —
TEZSPIRE
$368 — —
ACTHAR
$290 — —
PURIFIED CORTROPHIN GEL
$264 — —
GLASSIA
$194 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

694 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record